These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28444181)

  • 1. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
    Golpanian S; DiFede DL; Khan A; Schulman IH; Landin AM; Tompkins BA; Heldman AW; Miki R; Goldstein BJ; Mushtaq M; Levis-Dusseau S; Byrnes JJ; Lowery M; Natsumeda M; Delgado C; Saltzman R; Vidro-Casiano M; Pujol MV; Da Fonseca M; Oliva AA; Green G; Premer C; Medina A; Valasaki K; Florea V; Anderson E; El-Khorazaty J; Mendizabal A; Goldschmidt-Clermont PJ; Hare JM
    J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1505-1512. PubMed ID: 28444181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Tompkins BA; DiFede DL; Khan A; Landin AM; Schulman IH; Pujol MV; Heldman AW; Miki R; Goldschmidt-Clermont PJ; Goldstein BJ; Mushtaq M; Levis-Dusseau S; Byrnes JJ; Lowery M; Natsumeda M; Delgado C; Saltzman R; Vidro-Casiano M; Da Fonseca M; Golpanian S; Premer C; Medina A; Valasaki K; Florea V; Anderson E; El-Khorazaty J; Mendizabal A; Green G; Oliva AA; Hare JM
    J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1513-1522. PubMed ID: 28977399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
    Golpanian S; DiFede DL; Pujol MV; Lowery MH; Levis-Dusseau S; Goldstein BJ; Schulman IH; Longsomboon B; Wolf A; Khan A; Heldman AW; Goldschmidt-Clermont PJ; Hare JM
    Oncotarget; 2016 Mar; 7(11):11899-912. PubMed ID: 26933813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.
    Zhu Y; Huang C; Zheng L; Li Q; Ge J; Geng S; Zhai M; Chen X; Yuan H; Li Y; Jia W; Sun K; Li Y; Ye T; Zhao Z; Liu H; Liu Z; Jiang H
    Stem Cell Res Ther; 2024 Apr; 15(1):122. PubMed ID: 38679727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
    Hare JM; DiFede DL; Rieger AC; Florea V; Landin AM; El-Khorazaty J; Khan A; Mushtaq M; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Alfonso CE; Valasaki K; Pujol MV; Golpanian S; Ghersin E; Fishman JE; Pattany P; Gomes SA; Delgado C; Miki R; Abuzeid F; Vidro-Casiano M; Premer C; Medina A; Porras V; Hatzistergos KE; Anderson E; Mendizabal A; Mitrani R; Heldman AW
    J Am Coll Cardiol; 2017 Feb; 69(5):526-537. PubMed ID: 27856208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics.
    Zhu Y; Ge J; Huang C; Liu H; Jiang H
    Theranostics; 2021; 11(12):5675-5685. PubMed ID: 33897874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.
    Levy ML; Crawford JR; Dib N; Verkh L; Tankovich N; Cramer SC
    Stroke; 2019 Oct; 50(10):2835-2841. PubMed ID: 31495331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
    Glassberg MK; Minkiewicz J; Toonkel RL; Simonet ES; Rubio GA; DiFede D; Shafazand S; Khan A; Pujol MV; LaRussa VF; Lancaster LH; Rosen GD; Fishman J; Mageto YN; Mendizabal A; Hare JM
    Chest; 2017 May; 151(5):971-981. PubMed ID: 27890713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal Stem Cells for Frailty?
    Larrick JW; Mendelsohn AR
    Rejuvenation Res; 2017 Dec; 20(6):525-529. PubMed ID: 29179649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial.
    Díez-Tejedor E; Gutiérrez-Fernández M; Martínez-Sánchez P; Rodríguez-Frutos B; Ruiz-Ares G; Lara ML; Gimeno BF
    J Stroke Cerebrovasc Dis; 2014; 23(10):2694-2700. PubMed ID: 25304723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
    Hare JM; Traverse JH; Henry TD; Dib N; Strumpf RK; Schulman SP; Gerstenblith G; DeMaria AN; Denktas AE; Gammon RS; Hermiller JB; Reisman MA; Schaer GL; Sherman W
    J Am Coll Cardiol; 2009 Dec; 54(24):2277-86. PubMed ID: 19958962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
    Butler J; Epstein SE; Greene SJ; Quyyumi AA; Sikora S; Kim RJ; Anderson AS; Wilcox JE; Tankovich NI; Lipinski MJ; Ko YA; Margulies KB; Cole RT; Skopicki HA; Gheorghiade M
    Circ Res; 2017 Jan; 120(2):332-340. PubMed ID: 27856497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
    Florea V; Rieger AC; DiFede DL; El-Khorazaty J; Natsumeda M; Banerjee MN; Tompkins BA; Khan A; Schulman IH; Landin AM; Mushtaq M; Golpanian S; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Valasaki K; Pujol MV; Ghersin E; Miki R; Delgado C; Abuzeid F; Vidro-Casiano M; Saltzman RG; DaFonseca D; Caceres LV; Ramdas KN; Mendizabal A; Heldman AW; Mitrani RD; Hare JM
    Circ Res; 2017 Nov; 121(11):1279-1290. PubMed ID: 28923793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of frailty in older adults with mesenchymal stem cells.
    Florea V; Bagno L; Rieger AC; Hare JM
    Mech Ageing Dev; 2019 Jul; 181():47-58. PubMed ID: 31181214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Schiess M; Suescun J; Doursout MF; Adams C; Green C; Saltarrelli JG; Savitz S; Ellmore TM
    Mov Disord; 2021 Aug; 36(8):1825-1834. PubMed ID: 33772873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frailty and Rejuvenation with Stem Cells: Therapeutic Opportunities and Clinical Challenges.
    Sun XL; Hao QK; Tang RJ; Xiao C; Ge ML; Dong BR
    Rejuvenation Res; 2019 Dec; 22(6):484-497. PubMed ID: 30693831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
    Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
    Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study.
    Yang Y; Pang M; Du C; Liu ZY; Chen ZH; Wang NX; Zhang LM; Chen YY; Mo J; Dong JW; Xie PG; Wang QY; Liu B; Rong LM
    Cytotherapy; 2021 Jan; 23(1):57-64. PubMed ID: 33218835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis.
    Roesch EA; Bonfield TL; Lazarus HM; Reese J; Hilliard K; Hilliard J; Khan U; Heltshe S; Gluvna A; Dasenbrook E; Caplan AI; Chmiel JF
    J Cyst Fibros; 2023 May; 22(3):407-413. PubMed ID: 36549988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.
    Álvaro-Gracia JM; Jover JA; García-Vicuña R; Carreño L; Alonso A; Marsal S; Blanco F; Martínez-Taboada VM; Taylor P; Martín-Martín C; DelaRosa O; Tagarro I; Díaz-González F
    Ann Rheum Dis; 2017 Jan; 76(1):196-202. PubMed ID: 27269294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.